As of November 6, 2026, 7 holders' latest Schedule 13D or 13G filings report owning 5% or more of Assembly Biosciences, Inc. The largest reported stake is Gilead Sciences, Inc.'s, at 25.1%. 13 filings are on record since August 12, 2025 (Schedule 13D/A, May 27, 2026).
Sell to companies like Assembly Biosciences, Inc? Enter your website and see 10 with a filed reason to buy from you this month. Free.
Opens in a new tab. No signup.
Key facts
- · Holder: Paradigm BioCapital Advisors LP · Percent: 7.8% · SCHEDULE 13G/A
- · Holder: JANUS HENDERSON GROUP Ltd. · Percent: 6.9% · SCHEDULE 13G/A
- · Reporting person: Farallon Capital Management, L.L.C. · Sole voting: 0 · Shared voting: 1,604,590 · Sole dispositive: 0 · Shared dispositive: 1,604,590 · SCHEDULE 13G/A, 2026-08-04
- · Holder: Gilead Sciences, Inc. · Percent: 25.1% · SCHEDULE 13D/A
- · Holder: Paradigm BioCapital Advisors LP · Percent: 5.4% · SCHEDULE 13G
Assembly Biosciences, Inc. has 13 Schedule 13D or 13G filings on record since 2025-08-12. 7 holders' latest filing reports 5% or more of common stock, $0.001 par value per share. Each figure below is the holder's own, as filed, with the filing linked.
Holders
| Holder | Percent | Shares | Latest | Event date |
|---|---|---|---|---|
| Gilead Sciences, Inc. | 25.1% | 4,977,089 | SCHEDULE 13D/A, 2026-05-27 | 2026-05-22 |
| Commodore Capital LP | 9.9% | 1,615,981 | SCHEDULE 13G, 2025-08-15 | 2025-08-08 |
| RA Capital Management, L.P. | 9.5% | 1,530,615 | SCHEDULE 13G, 2025-08-18 | 2025-08-11 |
| Farallon Capital Management, L.L.C. | 8.1% | 1,604,590 | SCHEDULE 13G/A, 2026-08-04 | 2026-06-30 |
| 7.8% | 1,227,590 | SCHEDULE 13G/A, 2026-02-09 | 2025-12-31 | |
| Paradigm BioCapital Advisors LP | 7.8% | 1,553,748 | SCHEDULE 13G/A, 2026-08-14 | 2026-06-30 |
| JANUS HENDERSON GROUP Ltd. | 6.9% | 1,359,514 | SCHEDULE 13G/A, 2026-08-13 | 2026-06-30 |
| 3.49% | 543,523 | SCHEDULE 13G/A, 2025-08-18 | 2025-08-11 |
Holding shares or following this stake? See who's behind Assembly Biosciences, Inc. and the warning signs.
Free to see. No signup.
Keep reading
More on Assembly Biosciences, Inc. and the records around it.
Assembly Biosciences, Inc. elsewhere on the record
Companies that share a holder
- GILEAD SCIENCES, INC. also filed stake reports on 5 other companies: Aspen Neuroscience, Inc. (Nov 2026), Arcus Biosciences, Inc. (Aug 2026), Arcellx, Inc. (Apr 2026)
- Farallon Capital Management, L.L.C. also filed stake reports on 18 other companies: EXELIXIS, INC. (Nov 2026), ENANTA PHARMACEUTICALS INC (Aug 2026), InflaRx N.V. (Aug 2026)
- Farallon Capital Partners, L.P. also filed stake reports on 19 other companies: BridgeBio Pharma, Inc. (May 2026), InflaRx N.V. (May 2026), Beta Bionics, Inc. (May 2026)
Watch Assembly Biosciences, Inc.
Get an email when Assembly Biosciences, Inc. files again: a new raise, a leadership change, a layoff or an IPO filing. One email first to confirm; nothing else until you click it. At most one a day, one click to stop. Free for up to 3 companies.
Want the whole picture on Assembly Biosciences, Inc.?
Example from a real report (our sample on Target): “Target eliminated approximately 1,800 corporate positions, with around 1,000 employees receiving layoff notices and the remainder accounted for by eliminating open roles.” Source: NBC News
A Full Report on Assembly Biosciences, Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on Assembly Biosciences, Inc. covers
The Short Answer
Which Company This Is
What They Do, And How The Money Works
Who Runs It, And How To Reach Them
The Money: Funding, Valuation, Runway
Who Pays Them, And Who They Are Up Against
Warning Bells
Sources
13 cited sources found
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
Not ready to order yet? Keep this snapshot.
Sends this preview to you once; we won't add you to any list
Voting and dispositive power, as filed
| Reporting person | Sole voting | Shared voting | Sole dispositive | Shared dispositive | Filing |
|---|---|---|---|---|---|
| Farallon Capital Management, L.L.C. | 0 | 1,604,590 | 0 | 1,604,590 | SCHEDULE 13G/A, 2026-08-04 |
| Farallon Capital Partners, L.P. | 0 | 0 | 0 | 0 | SCHEDULE 13G/A, 2026-08-04 |
| Farallon Capital Institutional Partners, L.P. | 0 | 0 | 0 | 0 | SCHEDULE 13G/A, 2026-08-04 |
| Farallon Capital Institutional Partners II, L.P. | 0 | 0 | 0 | 0 | SCHEDULE 13G/A, 2026-08-04 |
| Farallon Capital Institutional Partners III, L.P. | 0 | 0 | 0 | 0 | SCHEDULE 13G/A, 2026-08-04 |
| Four Crossings Institutional Partners V, L.P. | 0 | 0 | 0 | 0 | SCHEDULE 13G/A, 2026-08-04 |
| Farallon Capital Offshore Investors II, L.P. | 0 | 0 | 0 | 0 | SCHEDULE 13G/A, 2026-08-04 |
| Farallon Capital (AM) Investors, L.P. | 0 | 0 | 0 | 0 | SCHEDULE 13G/A, 2026-08-04 |
| Farallon Capital F5 Master I, L.P. | 0 | 0 | 0 | 0 | SCHEDULE 13G/A, 2026-08-04 |
| Farallon Partners, L.L.C. | 0 | 0 | 0 | 0 | SCHEDULE 13G/A, 2026-08-04 |
| Farallon Institutional (GP) V, L.L.C. | 0 | 0 | 0 | 0 | SCHEDULE 13G/A, 2026-08-04 |
| Farallon F5 (GP), L.L.C. | 0 | 0 | 0 | 0 | SCHEDULE 13G/A, 2026-08-04 |
| Dapice Joshua J. | 0 | 1,604,590 | 0 | 1,604,590 | SCHEDULE 13G/A, 2026-08-04 |
| Dreyfuss, Philip D. | 0 | 1,604,590 | 0 | 1,604,590 | SCHEDULE 13G/A, 2026-08-04 |
| Dunn Hannah E. | 0 | 1,604,590 | 0 | 1,604,590 | SCHEDULE 13G/A, 2026-08-04 |
| Gehani, Varun N. | 0 | 1,604,590 | 0 | 1,604,590 | SCHEDULE 13G/A, 2026-08-04 |
| Giauque, Nicolas | 0 | 1,604,590 | 0 | 1,604,590 | SCHEDULE 13G/A, 2026-08-04 |
| Husen, Avner A. | 0 | 1,604,590 | 0 | 1,604,590 | SCHEDULE 13G/A, 2026-08-04 |
| Kim, David T. | 0 | 1,604,590 | 0 | 1,604,590 | SCHEDULE 13G/A, 2026-08-04 |
| Linn, Michael G. | 0 | 1,604,590 | 0 | 1,604,590 | SCHEDULE 13G/A, 2026-08-04 |
| Luo Patrick (Cheng) | 0 | 1,604,590 | 0 | 1,604,590 | SCHEDULE 13G/A, 2026-08-04 |
| Roberts, Jr., Thomas G. | 0 | 1,604,590 | 0 | 1,604,590 | SCHEDULE 13G/A, 2026-08-04 |
| Saito Edric C. | 0 | 1,604,590 | 0 | 1,604,590 | SCHEDULE 13G/A, 2026-08-04 |
| Short Daniel S. | 0 | 1,604,590 | 0 | 1,604,590 | SCHEDULE 13G/A, 2026-08-04 |
The latest filing identifies Assembly Biosciences, Inc. by CUSIP 045396207 and gives its principal executive office as Two Tower Place, 7th Floor, South San Francisco, CA 94080 (SCHEDULE 13G/A, 2026-08-14).
What the percentages are based on
See Item 11 on the cover page for each Reporting Person.Paradigm BioCapital Advisors LP, SCHEDULE 13G/A, 2026-08-14
Timeline
| Filed | Holder | Percent | Filing |
|---|---|---|---|
| 2025-08-12 | Alexander Schornstein | 4.68% | SCHEDULE 13G |
| 2025-08-12 | Gilead Sciences, Inc. | 29% | SCHEDULE 13D/A |
| 2025-08-15 | Dapice Joshua J. | 7.3% | SCHEDULE 13G |
| 2025-08-15 | Commodore Capital LP | 9.9% | SCHEDULE 13G |
| 2025-08-18 | Alexander Schornstein | 3.49% | SCHEDULE 13G/A |
| 2025-08-18 | RA Capital Management, L.P. | 9.5% | SCHEDULE 13G |
| 2025-12-08 | Janus Henderson Group Plc | 8.2% | SCHEDULE 13G |
| 2026-02-09 | Dapice Joshua J. | 7.8% | SCHEDULE 13G/A |
| 2026-05-11 | Paradigm BioCapital Advisors LP | 5.4% | SCHEDULE 13G |
| 2026-05-27 | Gilead Sciences, Inc. | 25.1% | SCHEDULE 13D/A |
| 2026-08-04 | Farallon Capital Management, L.L.C. | 8.1% | SCHEDULE 13G/A |
| 2026-08-13 | JANUS HENDERSON GROUP Ltd. | 6.9% | SCHEDULE 13G/A |
| 2026-08-14 | Paradigm BioCapital Advisors LP | 7.8% | SCHEDULE 13G/A |
Questions about who owns Assembly Biosciences, Inc.
Who owns Assembly Biosciences, Inc.?
On this page, 7 holders' latest ownership filings report 5% or more of Assembly Biosciences, Inc.: Gilead Sciences, Inc. (25.1%, Schedule 13D/A, filed 2026-05-27), Commodore Capital LP (9.9%, Schedule 13G, filed 2025-08-15), RA Capital Management, L.P. (9.5%, Schedule 13G, filed 2025-08-18), Farallon Capital Management, L.L.C. (8.1%, Schedule 13G/A, filed 2026-08-04) and Dapice Joshua J. (7.8%, Schedule 13G/A, filed 2026-02-09); 2 more are listed above.
Who are the largest shareholders of Assembly Biosciences, Inc.?
By the share each holder's latest filing reports, the largest holders of Assembly Biosciences, Inc. on this page are Gilead Sciences, Inc. (25.1%), Commodore Capital LP (9.9%) and RA Capital Management, L.P. (9.5%).
When did Gilead Sciences, Inc. buy into Assembly Biosciences, Inc.?
The filings give report dates, not purchase dates. The earliest filing from Gilead Sciences, Inc. on this page is the Schedule 13D/A, filed 2025-08-12, reporting 29%; its latest, Schedule 13D/A filed 2026-05-27, reports 25.1%. That earliest filing is itself an amendment, which updates an earlier report.
Is this an audit or a full list?
Neither. The ownership list on this page covers only Schedule 13D and 13G filings, which holders make once they own 5% or more of a class of shares (an amendment can report a stake that has since fallen below 5%); 13 such filings are shown here. It is not an audit and not a full cap table: holders who never reached 5% are not listed, and a stake can change after its latest filing.
Tools for this story
Each opens in a new tab, filled in for Assembly Biosciences, Inc.. With no account yet, you sign up free and land on the result.
Where this comes from
Anyone who comes to own more than 5% of a class of a listed company's voting shares has to tell the SEC. A holder who may seek to change or influence the company files Schedule 13D, and has to say in Item 4, "Purpose of Transaction", what it intends to do. A holder with no such intent, such as many index and passive funds, may file the shorter Schedule 13G. Both are amended when the stake changes, including when it falls below 5%.
Every row here is one of those filings, linked to the filing itself. Percentages and share counts are exactly as the holder filed them, for the holder the filing names; an amendment showing a lower figure is shown as filed. Item 4 text is quoted word for word. Where a 13D's Item 4 contains a sentence stating a definite intent to influence the company, that sentence is marked and quoted; the page does not describe the holder or its motives beyond the words it filed. Nothing here is investment advice.